CDK4/6 inhibitors
Showing 1–12 of 14 results
Pending medical review. This educational content has not yet been approved by a named medical reviewer.
About CDK4/6 inhibitors
CDK4/6 inhibitors are targeted medicines that block cyclin-dependent kinases 4 and 6. These proteins help regulate progression through the cell cycle. In susceptible cancer cells, inhibiting CDK4 and CDK6 can slow or stop cell proliferation.
Medicines in this class
The DrMeds catalogue currently links this class with abemaciclib, palbociclib and ribociclib. Individual products, strengths and formulations are not automatically interchangeable. Selection and dosing require assessment by a qualified prescriber.
Use in cancer care
CDK4/6 inhibitors are prescription targeted therapies used in specific treatment settings, including certain hormone receptor-positive, HER2-negative breast cancers. Approved uses and combination regimens differ by medicine, patient characteristics and country. This directory is for education and catalogue navigation, not treatment selection.
Important safety information
Monitoring requirements, interactions, contraindications and adverse effects differ between medicines. Reported class and medicine-specific risks can include low blood-cell counts, infection, liver problems and other serious adverse effects. Patients should use these medicines only under specialist supervision and follow the current prescribing information for the exact product.
Frequently asked questions
What are CDK4/6 inhibitors?
They are targeted medicines that inhibit CDK4 and CDK6, proteins involved in cell-cycle progression.
Which molecules are listed in this class?
The current catalogue links abemaciclib, palbociclib and ribociclib to this class.
Are CDK4/6 inhibitors chemotherapy?
They are generally described as targeted therapies rather than traditional cytotoxic chemotherapy. Treatment plans may combine them with other medicines depending on the approved indication.
Can one CDK4/6 inhibitor be substituted for another?
No substitution should be made without the treating clinician. Approved uses, dosing, interactions, monitoring and safety profiles differ between medicines.
Medical sources
- National Cancer Institute — Abemaciclib: https://www.cancer.gov/about-cancer/treatment/drugs/abemaciclib
- National Cancer Institute — Palbociclib: https://www.cancer.gov/about-cancer/treatment/drugs/palbociclib
- National Cancer Institute — Targeted therapy drug list: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/approved-drug-list
- US Food and Drug Administration — CDK4/6 inhibitor lung-inflammation safety communication: https://www.fda.gov/safety/medical-product-safety-information/ibrance-palbociclib-kisqali-ribociclib-and-verzenio-abemaciclib-drug-safety-communication-due-rare